Literature DB >> 26004163

Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus.

Ahmed Q Haddad1, Bradley C Leibovich2, Edwin Jason Abel3, Jun-Hang Luo1, Laura-Maria Krabbe4, Robert Houston Thompson5, Jennifer E Heckman3, Megan M Merrill6, Bishoy A Gayed1, Arthur I Sagalowsky1, Stephen A Boorjian5, Christopher G Wood6, Vitaly Margulis7.   

Abstract

OBJECTIVE: Surgical resection for renal cell carcinoma (RCC) with suprahepatic inferior vena cava tumor thrombus is associated with significant morbidity, yet there are currently no tools for preoperative prognostic evaluation. Our goal was to develop a preoperative multivariable model for prediction of survival and risk of major complications in patients with suprahepatic thrombi.
METHODS: We identified patients who underwent surgery for RCC with suprahepatic tumor thrombus extension from 2000 to 2013 at 4 tertiary centers. A Cox proportional hazard model was used for analysis of overall survival (OS) and logistic regression was used for major complications within 90 days of surgery (Clavien ≥ 3A). Nomograms were internally calibrated by bootstrap resampling method.
RESULTS: A total of 49 patients with level III thrombus and 83 patients with level IV thrombus were identified. During median follow-up of 24.5 months, 80 patients (60.6%) died and 46 patients (34.8%) experienced major complication. Independent prognostic factors for OS included distant metastases at presentation (hazard ratio = 2.52, P = 0.002) and Eastern Cooperative Oncology Group (ECOG) performance status (hazard ratio = 1.84, P<0.0001). Variables associated with increased risk of major complications on univariate analysis included preoperative systemic symptoms, level IV thrombus, and elevated preoperative alkaline phosphatase and aspartate transaminase levels; however, only systemic symptoms (odds ratio = 8.45, P<0.0001) was an independent prognostic factor. Preoperative nomograms achieved a concordance index of 0.72 for OS and 0.83 for major complications.
CONCLUSIONS: We have developed and internally validated multivariable preoperative models for the prediction of survival and major complications in patients with RCC who have a suprahepatic inferior vena cava thrombus. If externally validated, these tools may aid in patient selection for surgical intervention.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Inferior vena cava; Nomogram; Prognosis; Renal cell carcinoma; Thrombus

Mesh:

Year:  2015        PMID: 26004163     DOI: 10.1016/j.urolonc.2015.04.010

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  13 in total

1.  The Significant Role of Tumor Volume on the Surgical Approach Choice, Surgical Complexity, and Postoperative Complications in Renal Cell Carcinoma With Venous Tumor Thrombus From a Large Chinese Center Experience.

Authors:  Qais Baheen; Zhuo Liu; Yichang Hao; Rejean R R Sawh; Yuxuan Li; Xun Zhao; Peng Hong; Zonglong Wu; Lulin Ma
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

2.  T.H.R.O.B.V.S. Score - A Comprehensive Model to Predict the Surgical Complexity of Renal Cell Carcinoma With Tumor Thrombus.

Authors:  Kai Wang; Zhuo Liu; Peng Hong; Yan-Chun Qin; Xun Zhao; Hong-Xian Zhang; Cheng Liu; Li-Yuan Ge; Lu-Lin Ma
Journal:  Front Oncol       Date:  2022-06-23       Impact factor: 5.738

3.  Prognostic Significance of a Novel Score Model Based on Preoperative Indicators in Patients with Breast Cancer Spine Metastases (BCSM).

Authors:  Chenglong Zhao; Yao Wang; Xiaopan Cai; Wei Xu; Dongsheng Wang; Ting Wang; Qi Jia; Haiyi Gong; Haitao Sun; Zhipeng Wu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2020-11-10       Impact factor: 3.989

4.  The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Authors:  Charles C Peyton; E Jason Abel; Juan Chipollini; David C Boulware; Mounsif Azizi; Jose A Karam; Vitaly Margulis; Viraj A Master; Surena F Matin; Jay D Raman; Wade J Sexton; Christopher G Wood; Philippe E Spiess
Journal:  Eur Urol Focus       Date:  2018-09-08

5.  Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial.

Authors:  Vitaly Margulis; Yuval Freifeld; Laurentiu M Pop; Subrata Manna; Payal Kapur; Ivan Pedrosa; Alana Christie; Osama Mohamad; Samantha Mannala; Nirmish Singla; Michael Wait; Aditya Bagrodia; Solomon L Woldu; Jeffrey Gahan; James Brugarolas; Robert Timmerman; Raquibul Hannan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-02-05       Impact factor: 8.013

6.  Predictors of Survival in Patients Undergoing Surgery for Renal Cell Carcinoma and Inferior Vena Cava Tumor Thrombus.

Authors:  Alberto C Pieretti; Manuel Ozambela; Mary E Westerman; Graciela M Nogueras-Gonzalez; Luis A Segarra; Niki M Zacharias; Ara Vaporciyan; Wayne Hofstetter; Tam Huynh; Saad Aldousari; Surena F Matin; Jose A Karam
Journal:  Clin Genitourin Cancer       Date:  2022-02-09       Impact factor: 3.121

7.  Preoperative Gamma-Glutamyltransferase Is Associated with Cancer-Specific Survival and Recurrence-Free Survival of Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus.

Authors:  Cheng Luo; Ben Xu; Yu Fan; Wei Yu; Qian Zhang; Jie Jin
Journal:  Biomed Res Int       Date:  2017-01-11       Impact factor: 3.411

Review 8.  Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.

Authors:  Brian M Shinder; Kevin Rhee; Douglas Farrell; Nicholas J Farber; Mark N Stein; Thomas L Jang; Eric A Singer
Journal:  Front Oncol       Date:  2017-05-31       Impact factor: 6.244

9.  Deep Vein Thrombosis in Upper Limb in a Weightlifter.

Authors:  Montserrat Pérez Pinar; Regina Pastor Toledo; Luis Broseta Viana; Julián Solís García Del Pozo
Journal:  Open Access Maced J Med Sci       Date:  2017-03-06

10.  Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report.

Authors:  Andrea Benedetto Galosi; Alessio Papaveri; Daniele Castellani; Edoardo Agostini; Luciano Burattini; Lucio Dell'Atti
Journal:  Urol Case Rep       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.